SCHEMBL4480734

SCHEMBL4480734

Cc1cc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)c(F)c2)ccc1Cl

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 14/20 0.75
KIT P10721 10/20 0.75
FLT3 P36888 10/20 0.75
PLK4 O00444 8/20 0.64
MAP4K4 O95819 8/20 0.64
MARK3 P27448 8/20 0.64
AXL P30530 8/20 0.64
MAP4K2 Q12851 8/20 0.64
STK3 Q13188 8/20 0.64
SLK Q9H2G2 8/20 0.64
MKNK2 Q9HBH9 8/20 0.64
LCK P06239 8/20 0.64
AURKA O14965 7/20 0.64
BLK P51451 7/20 0.64
LIMK1 P53667 7/20 0.64
MARK2 Q7KZI7 7/20 0.64
CLK4 Q9HAZ1 7/20 0.64
CSNK1G2 P78368 6/20 0.64
CAMK2G Q13555 6/20 0.64
CAMK2D Q13557 6/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4477226 0.87 KDR (0.85) KDRKITFLT3PLK4MAP4K4
SCHEMBL4481371 0.86 KDR (1.00) KDRKITFLT3PLK4MAP4K4
SCHEMBL4466145 0.86 KDR (0.79) KDRKITFLT3PLK4MAP4K4
SCHEMBL4485286 0.84 KDR (0.80) KDRKITFLT3PLK4MAP4K4
SCHEMBL4474210 0.82 KDR (1.00) KDRKITFLT3PLK4MAP4K4
SCHEMBL4466205 0.80 KDR (0.77) KDRKITFLT3PLK4MAP4K4
SCHEMBL4463114 0.80 KDR (0.76) KDRKITFLT3PLK4MAP4K4
SCHEMBL4467381 0.80 KIT (0.82) KDRKITFLT3PLK4MAP4K4
SCHEMBL4486457 0.80 KDR (0.75) KDRKITFLT3PLK4MAP4K4
SCHEMBL4486498 0.79 KIT (0.82) KDRKITFLT3PLK4MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487841-B1 THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS ABBVIE INC (US) 2014-01-15 EP disclosed
US-7560552-B2 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES (US) 2009-07-14 US disclosed
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors MICHAELIDES MICHAEL R 2006-12-07 US disclosed
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBVIE INC. 2004-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 425/4885KIT 394/4885FLT3 29/4885
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors ABL1, LCK, ERBB2 KDR 391/4885KIT 361/4885FLT3 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.